Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre hospitalier de l'Université de Montréal (CHUM)
METHODS
Objectives
The primary objective will be to measure the hemodynamic effects of vasopressin on portal pressure in cirrhotic patients who have had a hypovolemic phlebotomy during a liver transplant.
The secondary objectives will be to measure the effects of vasopressin on portal pressure in patients who have not had a phlebotomy and to compare this effect between patients who have or have not had a hypovolemic phlebotomy.
The tertiary objective will be to assess the effect of the variation in portal pressure under vasopressin, associated or not with a hypovolemic phlebotomy, on hemorrhagic clinical outcomes (intraoperative bleeding and blood transfusions).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Cirrhotic patients undergoing a liver transplantation
18 years and older
Planned use of vasopressin during the surgery
You may not be if
Fulminant or sub-fulminant hepatitis without underlying chronic liver disease
Anesthetic plan does not include the use of vasopressin (contraindication or not relevant according to the anesthesiologist)